AR045033A1 - Derivados de malonamida, metodo de obtencion y composiciones farmaceuticas que los contienen. - Google Patents
Derivados de malonamida, metodo de obtencion y composiciones farmaceuticas que los contienen.Info
- Publication number
- AR045033A1 AR045033A1 ARP040102386A ARP040102386A AR045033A1 AR 045033 A1 AR045033 A1 AR 045033A1 AR P040102386 A ARP040102386 A AR P040102386A AR P040102386 A ARP040102386 A AR P040102386A AR 045033 A1 AR045033 A1 AR 045033A1
- Authority
- AR
- Argentina
- Prior art keywords
- halogen
- atoms
- substituted
- group
- optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C233/15—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se refiere a derivados de malonamida de la fórmula (1) A-D-B en donde D es un resto de malonamida bivalente sustituido o insustituido o uno de sus derivados: A es un resto insustituido o sustituido de hasta 40 átomos de C de la fórmula -L-(M-L´)a´ en donde L es una estructura cíclica de 5, 6 o 7 miembros seleccionada, con preferencia, del grupo integrado por arilo, heteroarilo, arileno y heteroarileno, unida directamente con D; L´ comprende un resto cíclico opcionalmente sustituido que tiene al menos 5 miembros seleccionado, con preferencia, del grupo integrado por arilo, heteroarilo, aralquilo, cicloalquilo y heterociclilo, M es un enlace o un grupo puente que tiene al menos un átomo, a es un número entero de 1 a 4; y cada estructura cíclica de L y L´ contiene 0-4 miembros del grupo integrado por N, O y S, en donde L´ está sustituido, con preferencia, con al menos un sustituyente seleccionado del grupo integrado por SObRx, -C(O)Rx y -C(NRy)Rz; B es un resto arilo o heteroarilo sustituido o insustituido hasta tricíclico de hasta 30 átomos de C, con preferencia, de hasta 20 átomos de C, que comprende al menos una estructura cíclica de 5, 6 o 7 miembros, con preferencia, una estructura cíclica de 5 o 6 miembros, unida directamente con D que contiene 0-4 miembros del grupo integrado por N, O y S, en donde dicha estructura cíclica directamente unida a D está seleccionada, con preferencia, del grupo integrado por arilo, heteroarilo y heterociclilo; Ry es H o un resto carbonado de hasta 24 átomos de C que opcionalmente contiene heteroátomos seleccionados de N, s y O que está opcionalmente halosustituido, hasta perhalo; Rz es H o u resto carbonado de hasta 30 átomos de C que opcionalmente contiene heteroátomos seleccionados de N, S y O y que está opcionalmente sustituido con halógeno, hidroxi y sustituyentes carbonados de hasta 24 átomos de C, que opcionalmente contienen heteroátomos seleccionados de N, S y O y que están opcionalmente sustituidos con halógeno; Rx es Rz o NRaRb, en donde Ra y Rb son a) de forma independiente, H, un resto carbonado de hasta 30 átomos de C que opcionalmente contiene heteroátomos seleccionados de N, S y O y que está opcionalmente sustituido con halógeno, hidroxi y sustituyentes carbonados de hasta 24 átomos de C, que opcionalmente contienen heteroátomos seleccionados de N, S y O y que están opcionalmente sustituidos con halógeno, u -OSi(Rf)3, en donde Rf es H o un resto carbonado de hasta 24 átomos de C que opcionalmente contiene heteroátomos seleccionados de N, S y O y que está opcionalmente sustituido con halógeno, hidroxi y sustituyentes carbonados de hasta 24 átomos de C que opcionalmente contienen heteroátomos seleccionados de N, S y O y que están opcionalmente sustituidos con halógeno; o b) Ra y Rb forman juntos una estructura heterocíclica de 5-7 miembros de 1-3 heteroátomos seleccionados de N, S y O, o una estructura heterocíclica sustituida de 5-7 miembros de 1-3 heteroátomos seleccionados de N, S y O sustituida con halógeno, hidroxi o sustituyentes carbonados de hasta 24 átomos de C, que opcionalmente contienen heteroátomos seleccionados de N, S y O y que están opcionalmente sustituidos con halógeno; o c) uno de Ra o Rb es -C(O)-, un grupo alquileno C1-5 divalente o un grupo alquileno C1-5 divalente sustituido unido con el resto L para formar una estructura cíclica con al menos 5 miembros, en donde los sustituyentes del grupo alquileno C1-5 divalente sustituido están seleccionados del grupo integrado por halógeno, hidroxi y sustituyentes carbonados de hasta 24 átomos de C, que opcionalmente contienen heteroátomos seleccionados de N, S y O y que están opcionalmente sustituidos con halógeno; en donde B está sustituido, L está sustituido o L´ está adicionalmente sustituido, los sustituyentes están seleccionados del grupo integrado por halógeno, hasta perhalo, y Wg, en donde g es 0-3; en donde cada W está seleccionado, de forma independiente, del grupo integrado por -CN, -CO2R, -C(O)NR5R6, -C(O)-R5, -NO2, -OR5, -SR5, SO2R5, -SO3H, -NR5R5, -NR5C(O)OR5, -NR5C(O)R5, -Q-Ar, y restos carbonados de hasta 24 átomos de C, que opcionalmente contienen heteroátomos seleccionados de N, S y O y que están opcionalmente sustituidos con uno o varios sustituyentes seleccionados, de forma independiente, de los grupos integrados por -CN, -CO2R, -C(O)NR5R5, -C(O)-R5, -NO2, -OR5, -SR5, -SO2R5, -SO3H, -NR5R5, -NR5C(O)OR5, -NR5C(O)R5 y halógeno hasta perhalo; con cada R5 seleccionado, de forma independiente, de H o un resto carbonado de hasta 24 átomos de C, que opcionalmente contiene heteroátomos seleccionados de N, S y O y que está opcionalmente sustituido con halógeno, en donde Q es -O-, -S-, -N(R5)-, -(CH2)b, -C(O)-,-CH(OH)-, -(CH2)b-O-, -(CH2)b-S-, -(CH2)bN(R5), -O(CH2)b, -CHHal-, -CHal2-,-S-(CH2)- y -N(R5)(CH2)b-, en donde b = 1-3, y Hal es halógeno; y Ar es una estructura aromática de 5 o 6 miembros que contiene 0-2 miembros seleccionados del grupo integrado por N, O y S, que está opcionalmente sustituida con halógeno, hasta perhalo, y opcionalmente sustituida con Zd1, en donde d1 es 0 a 3 y cada Z está seleccionado, de forma independiente, del grupo integrado por -CN, -CO2R5, -C(O)NR5R5, -C(O)-R5, -NO2,-OR5, -SR5, -SO2R5, -SO3H, -NR5R5, -NR5C(O)OR5, -NR5C(O)R5, y un resto carbonado de hasta 24 átomos de C, que opcionalmente contiene heteroátomos seleccionados de N, S y O y que está opcionalmente sustituido con uno o varios sustituyentes seleccionados del grupo integrado por -CN, -CO2R5, -C(O)NR5R5, -C(O)-R5, -NO2, -OR5, -SR5, -SO2R5, -SO2R5, -SO3H., -NR5R5, -NR5C(O)OR5, -NR5C(O)R5, y sus derivados, sales y solvatos fisiológicamente aceptables. Al uso de los compuestos de la fórmula (1) para preparar una composición farmacéutica y a un método de tratamiento que comprende la administración de dicha composición farmacéutica a un paciente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03014556 | 2003-07-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045033A1 true AR045033A1 (es) | 2005-10-12 |
Family
ID=34042809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102386A AR045033A1 (es) | 2003-07-07 | 2004-07-07 | Derivados de malonamida, metodo de obtencion y composiciones farmaceuticas que los contienen. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070213374A1 (es) |
EP (1) | EP1641759B1 (es) |
JP (1) | JP4750701B2 (es) |
AR (1) | AR045033A1 (es) |
AU (1) | AU2004255566B2 (es) |
CA (1) | CA2531485C (es) |
WO (1) | WO2005005389A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1478358B1 (en) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
EP1626714B1 (en) | 2003-05-20 | 2007-07-04 | Bayer Pharmaceuticals Corporation | Diaryl ureas for diseases mediated by pdgfr |
SI1663978T1 (sl) | 2003-07-23 | 2008-02-29 | Bayer Pharmaceuticals Corp | Fluoro substituirana omega-karboksiaril difenil secnina za zdravljenje ali preprecevanje bolezni instanj |
DK2210607T3 (da) | 2003-09-26 | 2011-12-12 | Exelixis Inc | N-[3-fluor-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid til behandling af kræft |
TW200538097A (en) | 2004-02-27 | 2005-12-01 | Eisai Co Ltd | Novel pyridine derivative and pyrimidine derivative |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
CN101128199B (zh) * | 2004-04-23 | 2013-07-24 | 布里斯托尔-迈尔斯斯奎布公司 | 作为激酶抑制剂的单环杂环 |
WO2006014325A2 (en) * | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
US7470693B2 (en) | 2005-04-21 | 2008-12-30 | Bristol-Myers Squibb Company | Oxalamide derivatives as kinase inhibitors |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
SI1889836T1 (sl) | 2005-08-24 | 2013-10-30 | Eisai R&D Management Co., Ltd. | Nov derivat piridina in derivat piridina (3) |
CN101454311B (zh) | 2006-08-23 | 2013-03-27 | 卫材R&D管理有限公司 | 苯氧基吡啶衍生物的盐和其结晶及其制备方法 |
US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
NZ618004A (en) | 2009-01-16 | 2015-06-26 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
TWI520962B (zh) * | 2012-06-29 | 2016-02-11 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives | |
WO2018035346A1 (en) * | 2016-08-17 | 2018-02-22 | Ichan School Of Medicine At Mount Sinal | Kinase inhibitor compounds, compositions, and methods of treating cancer |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3574249D1 (en) * | 1984-02-08 | 1989-12-21 | Sawai Seiyaku Kk | Û(1,3,-dioxo-1,3-propanediyl)diimino¨ bisbenzoic acid derivatives and their use |
JP3380237B2 (ja) * | 1988-09-12 | 2003-02-24 | ファルマシア・アンド・アップジョン・カンパニー | 2のcpiサブユニットを有する新規cc―1065アナログ類 |
JP2627238B2 (ja) * | 1992-12-02 | 1997-07-02 | 富士写真フイルム株式会社 | マロン酸ジアミド化合物の製造方法 |
JPH08295667A (ja) * | 1995-04-27 | 1996-11-12 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および剤 |
TR200002618T2 (tr) * | 1997-12-22 | 2001-04-20 | Bayer Corporation | Sübstitüe edilmiş heterosiklik üreler kullanılarak raf kinazın inhibe edilmesi |
JP4261639B2 (ja) * | 1998-08-05 | 2009-04-30 | 日本曹達株式会社 | フェニルイミダゾール系抗高脂血症薬 |
CA2348267A1 (en) * | 1998-10-29 | 2000-05-11 | Henry H. Gu | Novel inhibitors of impdh enzyme |
EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
JP3528152B2 (ja) | 2000-01-17 | 2004-05-17 | 有限会社ひので屋 | 豆腐製造用撹拌器具 |
US6916846B2 (en) * | 2000-05-12 | 2005-07-12 | Merck & Co. Inc. | Coumermycin analogs as chemical dimerizers of chimeric proteins |
JP2004523490A (ja) * | 2000-11-28 | 2004-08-05 | ギルフォード ファーマシュウティカルズ インコーポレイテッド | 二置換カルボサイクリックサイクロフィリン結合化合物とその用途 |
DE10112771A1 (de) * | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
KR100883731B1 (ko) | 2001-06-22 | 2009-02-12 | 기린 파마 가부시끼가이샤 | 간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물 |
CA2744893A1 (en) * | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
CN1678314A (zh) * | 2002-08-27 | 2005-10-05 | 默克专利有限公司 | 作为raf-激酶抑制剂的甘氨酸酰胺衍生物 |
US7589112B2 (en) * | 2002-10-24 | 2009-09-15 | Merck Patent Gmbh | Methylene urea derivatives |
EP1641458A2 (en) * | 2002-12-27 | 2006-04-05 | Schering Aktiengesellschaft | Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors |
-
2004
- 2004-06-18 WO PCT/EP2004/006573 patent/WO2005005389A2/en active Application Filing
- 2004-06-18 US US10/563,830 patent/US20070213374A1/en not_active Abandoned
- 2004-06-18 CA CA2531485A patent/CA2531485C/en not_active Expired - Fee Related
- 2004-06-18 EP EP04740026.2A patent/EP1641759B1/en not_active Expired - Lifetime
- 2004-06-18 AU AU2004255566A patent/AU2004255566B2/en not_active Ceased
- 2004-06-18 JP JP2006518009A patent/JP4750701B2/ja not_active Expired - Fee Related
- 2004-07-07 AR ARP040102386A patent/AR045033A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP4750701B2 (ja) | 2011-08-17 |
WO2005005389A3 (en) | 2005-03-24 |
US20070213374A1 (en) | 2007-09-13 |
AU2004255566A1 (en) | 2005-01-20 |
EP1641759A2 (en) | 2006-04-05 |
JP2007508238A (ja) | 2007-04-05 |
EP1641759B1 (en) | 2014-03-12 |
AU2004255566B2 (en) | 2010-07-08 |
CA2531485A1 (en) | 2005-01-20 |
CA2531485C (en) | 2013-03-26 |
WO2005005389A2 (en) | 2005-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR045033A1 (es) | Derivados de malonamida, metodo de obtencion y composiciones farmaceuticas que los contienen. | |
AR041719A1 (es) | Derivados de metilenurea como inhibidores de la raf-quinasa | |
AR043047A1 (es) | Derivados de glicinamida | |
AR043757A1 (es) | Derivados de oxamida utilizados como inhibidores de la raf-quinasa | |
AR048484A1 (es) | Derivados de diacilhidrazina, su uso como inhibidor de raf quinasa y composiciones farmaceuticas que los contienen | |
AR115326A1 (es) | Inhibidores heterobicíclicos de mat2a y métodos de uso para tratar el cáncer | |
AR035371A1 (es) | Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento | |
AR110782A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa | |
AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
AR117544A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
UY29886A1 (es) | Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones | |
AR045386A1 (es) | [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
RU2008100164A (ru) | Получение и применение соединений в качестве ингибиторов протеаз | |
AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
AR041170A1 (es) | Derivados de bencimidazol, benzoxazol y benzotiazol | |
RU2007116987A (ru) | Новые соединения | |
CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
AR082886A1 (es) | Compuestos y composiciones farmaceuticas que los contienen | |
AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
AR017325A1 (es) | Derivados tetraciclicos de tetrahidrofurano halogeno sustituidos, un proceso para su preparacion, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento | |
AR041875A1 (es) | Compuesto de fenilo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento y procedimiento para preparar dicho compuesto | |
AR067060A1 (es) | Derivados de guanina policiclicos y sus metodos de uso | |
ATE493404T1 (de) | Azabicyclo-(3,1,0)-hexan-derivate als modulatoren von dopamin-d3-rezeptoren | |
AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |